May 3, 2012 Glenn Alto, President and CEO, and Ed Connolly, COO, presented "Making it in Massachusetts: A Small Company's Road to the CMO Market" at Interphex 2012. For more details and to listen to an audio summary of their presentation visit: interphex.com/Education/Speakers/  May 2, 2012 Pharmalucence is conducting a voluntary recall of its Kit for the Preparation of Technetium Tc99m Pyrophosphate Injection, lot #220053, expiring June 30, 2012.  Details here: PDF February 22, 2012 The Massachusetts Life Sciences Center (MLSC) named Pharmalucence as one of 28 Massachusetts Life Sciences companies to receive a tax incentive in return for creating new jobs in the industry. The MLSC awarded a total of $21.2 million in tax incentives to 28 life sciences companies, which have promised to create 940 new jobs.  Details here: PDF January 23, 2012 Pharmalucence begins operations at our new Corporate Headquarters in Billerica Massachusetts.  While manufacturing operations and personnel remain in Bedford MA while our new facility project continues, all administrative staff has now relocated to 29 Dunham Road, Billerica, MA 01821.  Our toll free number remains 1-800-221-7554, but some employee direct dial numbers have changed. December 27, 2011 Pharmalucence Supplemental New Drug Application (sNDA) for the use of Sulfur Colloid Injection (SCI) in the localization of lymph nodes in melanoma patients has been accepted for review by FDA. July 29, 2011  Pharmalucence partners with Robert Bosch Packaging Technology, Inc. to supply State-of-the-Art Isolated Filling Equipment for its new Drug Production Facility in Billerica, MA. PDF July 25, 2011  Pharmalucence receives FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) in the localization of lymph nodes in breast cancer patients. PDF July 7, 2011  Pharmalucence partners with Integrated Project Services (IPS) for Design and Construction of State-of-the-Art Pharmaceutical Production Facility in Billerca MA. pdf March 2, 2011 Pharmalucence to cease manufacturing of Pulmolite® (Kit for the Preparation of Technetium Tc99m Albumin Aggregated for Injection).  Click here for details: PDF August 23, 2010 Pharmalucence Mebrofenin amended labeling approved by FDA, post-reconstitution expiry extended to 18 hours.  Click here to view new Mebrofenin product summary sheet and package insert: PDF June 3, 2010 Pharmalucence Announces Purchase of New Property in Billerica MA, to be Developed into New Corporate Headquarters and State-of-the-Art Drug Manufacturing Facility, beginning Summer 2010.
	Pharmalucence, Inc. is a leading provider of radiopharmaceuticals, including a broad range of Technetium Tc 99m cold kits. Pharmalucence is also a provider of contract and private label formulation development and manufacturing services of human injectables in either liquid or lyophilized form. We are currently building a new 70,000 sq. ft. facility and will become New England's first CMO to utilize isolated, aseptic technology in support of a wide array of customer needs, from small clinical fills up to full commercial scale production for markets worldwide.  LEARN MORE ABOUT US